



Central Asia Region
Country Operational Plan
FY 2015



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
HHS/CDC	505,625	7,194,375		7,700,000	0
PC		120,000		120,000	0
State		280,000		280,000	0
USAID		6,700,000	1,000,000	7,700,000	0
Total	505,625	14,294,375	1,000,000	15,800,000	0

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency				On Hold Amount	Total
	State	HHS/CDC	PC	USAID		
CIRC		0				0
HBHC	22,500	1,137,129		1,465,962	0	2,625,591
HKID		0				0
HLAB		1,007,610			0	1,007,610
HMBL		280,905			0	280,905
HMIN		74,681				74,681
HTXD		0				0
HTXS		898,940			0	898,940
HVAB		0				0
HVCT		613,140		1,633,769	0	2,246,909
HVMS	257,500	933,542	25,250	1,243,506	0	2,459,798
HVOP		143,140	0	43,278	0	186,418
HVSI		1,155,376		608,014	0	1,763,390
HVTB		0		504,626	0	504,626
IDUP		1,443,092		1,546,412	0	2,989,504
MTCT		0				0
OHSS		12,445	94,750	654,433	0	761,628



PDCS		0				0
PDTX		0				0
	280,000	7,700,000	120,000	7,700,000	0	15,800,000



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	2,429,522	0
HVTB	444,841	0
Total Technical Area Planned Funding:	2,874,363	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	740,000	0
HVSI	1,475,000	0
OHSS	575,000	0
Total Technical Area Planned Funding:	2,790,000	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	200,000	0
HVCT	1,956,629	0
HVOP	25,000	0
IDUP	2,302,653	0
Total Technical Area Planned Funding:	4,484,282	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	650,000	0



Total Technical Area Planned Funding:	650,000	0
--	----------------	----------

Technical Area Summary Indicators and Targets

Kazakhstan

Indicator Number	Label	2015	2016
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months		216
	Sex: Male		163
	Sex: Female		53
	Sum of Sex disaggregates		216
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months		66,603
	By Test Result: Negative		66,421
	By Test Result: Positive		182
	Sum of Test Result disaggregates		66,603
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex:		



	Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		45
	Test Result by Age and Sex: Positive: 25-49 Male		63
	Test Result by Age and Sex: Positive: 50+ Male		12
	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		2
	Test Result by Age and Sex: Positive: 20-24 Female		14
	Test Result by Age and Sex: Positive: 25-49 Female		38
	Test Result by Age and Sex: Positive: 50+ Female		8
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex:		10



	Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		4,604
	Test Result by Age and Sex: Negative: 25-49 Male		4,785
	Test Result by Age and Sex: Negative: 50+ Male		729
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		26
	Test Result by Age and Sex: Negative: 20-24 Female		24,698
	Test Result by Age and Sex: Negative: 25-49 Female		29,955
	Test Result by Age and Sex: Negative: 50+ Female		1,614
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		10,248
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION		56,355

	ONLY: 15+ Female		
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		66,603
	Sum of Aggregated Age/Sex disaggregates		66,603
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by		



	Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		220
	Service Delivery Point by Result: Outpatient Department - Positive		54
	Service Delivery Point by Result: Outpatient Department - Negative		166

	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		66,383
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		128
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		66,255
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by		

	Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by		

	Result: Other - Negative		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		5,626
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		80
	Age/sex: 25-49 Male		3,163
	Age/sex: 50+ Male		187
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		9
	Age/sex: 20-24 Female		123
	Age/sex: 25-49 Female		1,876
	Age/sex: 50+ Female		188
	Sun of Age/Sex disaggregates		5,626
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		
Aggregated Age/sex - USE			

	WITH HQ PERMISSION ONLY: <15 Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		108
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		6
	Age/sex: 25-49 Male		42
	Age/sex: 50+ Male		8
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		2
	Age/sex: 20-24 Female		8
	Age/sex: 25-49 Female		34
	Age/sex: 50+ Female		8
	Sum of Age/sex disaggregates		108

	Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Male		
	Aggregated Age/sex: <15 Female		
	Aggregated Age/sex: 15+ Female		
	Sum of Aggregated Age/sex disaggregates		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		5,084
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		5,626
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		4
	Age: 20+		5,080
	Sum of Age disaggregates		5,084

	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		
	Sum of Aggregated Age disaggregates		
	Sex: Male		3,133
	Sex: Female		1,951
	Sum of Sex disaggregates		5,084
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)		2,217
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		2
	Age/Sex: 20+ Male		1,464
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		4
	Age/Sex: 20+ Female		747
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: 15+ Male		
	Aggregated Age/Sex: 1-14 Female		
Aggregated Age/Sex: 15+			

	Female		
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		
	Sum of Aggregated Age/Sex disaggregates		
	Aggregated Age/Sex: 1-14 Male		
	Sum of Aggregated Age/Sex (<1 and 1-14) <15		
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)		600
	By Age/Sex: <1 Male		
	By Age/Sex: 1-4 Male		
	By Age/Sex: 5-9 Male		
	By Age/Sex: 10-14 Male		
	By Age/Sex: 15-19 Male		
	By Age/Sex: 20-24 Male		4
	By Age/Sex: 25-49 Male		344
	By Age/Sex: 50+ Male		54
	By Age/Sex: <1 Female		
	By Age/Sex: 1-4 Female		
	By Age/Sex: 5-9 Female		
	By Age/Sex: 10-14 Female		
	By Age/Sex: 15-19 Female		
	By Age/Sex: 20-24 Female		16
	By Age/Sex: 25-49 Female		158
	By Age/Sex: 50+ Female		24
	Sum of Age/Sex disaggregates		600
	Aggregated Grouping by		

	Age: <1 Male		
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male		
	Aggregated Grouping by Age/Sex: <1 Female		
	Aggregated Grouping by Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
	Pregnancy status		
	Breastfeeding status		
	Aggregated Grouping by Age/Sex: 1-14 Female		
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		436
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		726
	Age/Sex: <5 Male (Numerator: Number of adults and children who are		

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		268
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are		

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		168
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have		

	died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		447
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who		

	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		279
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		933
	Number of adults and		1,232

	children on ART at least 6 months whose medical records were reviewed		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		582
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		1
	Age/Sex: 20+ Female		350
	Results Category: Undetectable		560
	Results Category: Detectable		373
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		1



Technical Area Summary Indicators and Targets

Kyrgyzstan

(No data provided.)

Technical Area Summary Indicators and Targets

Tajikistan

Indicator Number	Label	2015	2016
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months		1,339
	Sex: Male		1,209
	Sex: Female		130
	Sum of Sex disaggregates		1,339
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required		1,850
	Total estimated number of		

	key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		380
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		1,391
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		79
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with		

	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with		

	men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months		150,684
	By Test Result: Negative		117,171
	By Test Result: Positive		813
	Sum of Test Result disaggregates		117,984
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		82
	Test Result by Age and Sex: Positive: 25-49 Male		372



	Test Result by Age and Sex: Positive: 50+ Male		62
	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		34
	Test Result by Age and Sex: Positive: 25-49 Female		136
	Test Result by Age and Sex: Positive: 50+ Female		10
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		86
	Test Result by Age and Sex: Negative: 20-24 Male		15,890
	Test Result by Age and Sex: Negative: 25-49 Male		15,858
	Test Result by Age and Sex: Negative: 50+ Male		2,032

	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		58
	Test Result by Age and Sex: Negative: 20-24 Female		17,033
	Test Result by Age and Sex: Negative: 25-49 Female		95,893
	Test Result by Age and Sex: Negative: 50+ Female		1,134
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		36,109
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		114,575
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		150,684
	Sum of Aggregated Age/Sex disaggregates		150,684



	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child		

	Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		2,506
	Service Delivery Point by Result: Outpatient Department - Positive		408
	Service Delivery Point by Result: Outpatient Department - Negative		2,098
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		

	Service Delivery Point by Result: HIV care and treatment clinic – All Results		115,478
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		405
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		115,073
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		

	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4		3,424

	count OR viral load		
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		3
	Age/sex: 20-24 Male		31
	Age/sex: 25-49 Male		1,689
	Age/sex: 50+ Male		39
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		3
	Age/sex: 20-24 Female		79
	Age/sex: 25-49 Female		1,544
	Age/sex: 50+ Female		36
	Sun of Age/Sex disaggregates		3,424
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		

CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		724
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		32
	Age/sex: 25-49 Male		365
	Age/sex: 50+ Male		19
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		6
	Age/sex: 20-24 Female		26
	Age/sex: 25-49 Female		266
	Age/sex: 50+ Female		10
	Sum of Age/sex disaggregates		724
	Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Male		
Aggregated Age/sex: <15 Female			

	Aggregated Age/sex: 15+ Female		
	Sum of Aggregated Age/sex disaggregates		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		3,145
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		3,424
	Age: <1		0
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		3,145
	Sum of Age disaggregates		3,145
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		

	Sum of Aggregated Age disaggregates		
	Sex: Male		1,865
	Sex: Female		1,280
	Sum of Sex disaggregates		3,145
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)		2,016
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		4
	Age/Sex: 20+ Male		1,065
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		947
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: 15+ Male		
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		
	Sum of Aggregated Age/Sex		

	disaggregates		
	Aggregated Age/Sex: 1-14 Male		
	Sum of Aggregated Age/Sex (<1 and 1-14) <15		
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)		291
	By Age/Sex: <1 Male		
	By Age/Sex: 1-4 Male		
	By Age/Sex: 5-9 Male		
	By Age/Sex: 10-14 Male		
	By Age/Sex: 15-19 Male		4
	By Age/Sex: 20-24 Male		34
	By Age/Sex: 25-49 Male		125
	By Age/Sex: 50+ Male		22
	By Age/Sex: <1 Female		
	By Age/Sex: 1-4 Female		
	By Age/Sex: 5-9 Female		
	By Age/Sex: 10-14 Female		
	By Age/Sex: 15-19 Female		
	By Age/Sex: 20-24 Female		18
	By Age/Sex: 25-49 Female		80
	By Age/Sex: 50+ Female		8
	Sum of Age/Sex disaggregates		291
	Aggregated Grouping by Age: <1 Male		
	Aggregated Grouping by Age/Sex: 1-14 Male		
Aggregated Grouping by Age/Sex: 15+ Male			
Aggregated Grouping by			

	Age/Sex: <1 Female		
	Aggregated Grouping by Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
	Pregnancy status		
	Breastfeeding status		
	Aggregated Grouping by Age/Sex: 1-14 Female		
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		409
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		681
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are		

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		208
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are		200

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who		350

	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost		

	to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		331
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		853
	Number of adults and children on ART at least 6 months whose medical records were reviewed		1,000
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		

	Age/Sex: 15-19 Male		3
	Age/Sex: 20+ Male		454
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		396
	Results Category: Undetectable		692
	Results Category: Detectable		161
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		1



Technical Area Summary Indicators and Targets

Turkmenistan

(No data provided.)



Technical Area Summary Indicators and Targets

Uzbekistan

(No data provided.)

Technical Area Summary Indicators and Targets

Central Asia Region

Indicator Number	Label	2015	2016
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	70	1,555
	Sex: Male		1,372
	Sex: Female		183
	Sum of Sex disaggregates		1,555
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	26,822	1,850
	Total estimated number of		

	key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,668	380
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	18,033	1,391
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	79
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with	1,770	

	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with		

	men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,113	217,287
	By Test Result: Negative		183,592
	By Test Result: Positive		995
	Sum of Test Result disaggregates		184,587
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		127
	Test Result by Age and Sex: Positive: 25-49 Male		435

	Test Result by Age and Sex: Positive: 50+ Male		74
	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		2
	Test Result by Age and Sex: Positive: 20-24 Female		48
	Test Result by Age and Sex: Positive: 25-49 Female		174
	Test Result by Age and Sex: Positive: 50+ Female		18
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		96
	Test Result by Age and Sex: Negative: 20-24 Male		20,494
	Test Result by Age and Sex: Negative: 25-49 Male		20,643
	Test Result by Age and Sex: Negative: 50+ Male		2,761

	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		84
	Test Result by Age and Sex: Negative: 20-24 Female		41,731
	Test Result by Age and Sex: Negative: 25-49 Female		125,848
	Test Result by Age and Sex: Negative: 50+ Female		2,748
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		46,357
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		170,930
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		217,287
	Sum of Aggregated Age/Sex disaggregates		217,287

	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child		

	Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		2,726
	Service Delivery Point by Result: Outpatient Department - Positive		462
	Service Delivery Point by Result: Outpatient Department - Negative		2,264
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		

	Service Delivery Point by Result: HIV care and treatment clinic – All Results		181,861
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		533
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		181,328
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		

	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4		9,050

	count OR viral load		
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		3
	Age/sex: 20-24 Male		111
	Age/sex: 25-49 Male		4,852
	Age/sex: 50+ Male		226
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		12
	Age/sex: 20-24 Female		202
	Age/sex: 25-49 Female		3,420
	Age/sex: 50+ Female		224
	Sun of Age/Sex disaggregates		9,050
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		

CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		832
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		38
	Age/sex: 25-49 Male		407
	Age/sex: 50+ Male		27
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		8
	Age/sex: 20-24 Female		34
	Age/sex: 25-49 Female		300
	Age/sex: 50+ Female		18
	Sum of Age/sex disaggregates		832
	Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Male		
Aggregated Age/sex: <15 Female			

	Aggregated Age/sex: 15+ Female		
	Sum of Aggregated Age/sex disaggregates		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	1,200	8,229
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		9,050
	Age: <1		0
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		4
	Age: 20+		8,225
	Sum of Age disaggregates		8,229
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		

	Sum of Aggregated Age disaggregates		
	Sex: Male		4,998
	Sex: Female		3,231
	Sum of Sex disaggregates		8,229
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)		4,233
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		6
	Age/Sex: 20+ Male		2,529
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		4
	Age/Sex: 20+ Female		1,694
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: 15+ Male		
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		
	Sum of Aggregated Age/Sex		

	disaggregates		
	Aggregated Age/Sex: 1-14 Male		
	Sum of Aggregated Age/Sex (<1 and 1-14) <15		
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)		891
	By Age/Sex: <1 Male		
	By Age/Sex: 1-4 Male		
	By Age/Sex: 5-9 Male		
	By Age/Sex: 10-14 Male		
	By Age/Sex: 15-19 Male		4
	By Age/Sex: 20-24 Male		38
	By Age/Sex: 25-49 Male		469
	By Age/Sex: 50+ Male		76
	By Age/Sex: <1 Female		
	By Age/Sex: 1-4 Female		
	By Age/Sex: 5-9 Female		
	By Age/Sex: 10-14 Female		
	By Age/Sex: 15-19 Female		
	By Age/Sex: 20-24 Female		34
	By Age/Sex: 25-49 Female		238
	By Age/Sex: 50+ Female		32
	Sum of Age/Sex disaggregates		891
	Aggregated Grouping by Age: <1 Male		
	Aggregated Grouping by Age/Sex: 1-14 Male		
Aggregated Grouping by Age/Sex: 15+ Male			
Aggregated Grouping by			

	Age/Sex: <1 Female		
	Aggregated Grouping by Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
	Pregnancy status		
	Breastfeeding status		
	Aggregated Grouping by Age/Sex: 1-14 Female		
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		845
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		1,407
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are		

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		476
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are		368

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who		797

	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost		

	to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		610
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		1,786
	Number of adults and children on ART at least 6 months whose medical records were reviewed		2,232
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		

	Age/Sex: 15-19 Male		3
	Age/Sex: 20+ Male		1,036
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		1
	Age/Sex: 20+ Female		746
	Results Category: Undetectable		1,252
	Results Category: Detectable		534
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	11	2

Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
12026	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
12027	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12746	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	0
12772	United Nations Office on Drugs and Crime	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12799	Ministry of Health/Republican AIDS Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers	GHP-State	300,000

			for Disease Control and Prevention		
12812	Ministry of Health/Republican Narcology Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
12859	Population Services International	NGO	U.S. Agency for International Development	GHP-State	0
12872	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12889	Ministry of Health/Republican AIDS Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13501	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	0
13970	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000

13971	Republican Blood Center of the Ministry of Health of the Republic of Kazakhstan	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13972	Republican Blood Center of the Ministry of Health of the Kyrgyz Republic	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
13973	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	0
13974	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	200,000
13978	Republican Blood Center of the Ministry of Health of the Republic of Tajikistan	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
17050	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Agency for International Development	GHP-USAID	175,000
17051	AIDS Foundation East, West	NGO	U.S. Agency for International Development	GHP-State	0
17067	TBD	TBD	Redacted	Redacted	Redacted

17447	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0
17565	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,455,000
17776	Ministry of Health/Republican Narcology Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
17777	Ministry of Health/Republican Narcology Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
17778	TBD	TBD	Redacted	Redacted	Redacted
17812	New Partner	TBD	U.S. Agency for International Development	GHP-USAID	100,000
17813	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	300,000
18124	United Nations Office on Drug and Crime (UNODC)	Multi-lateral Agency	U.S. Agency for International Development	GHP-USAID	150,000



18155	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	0
-------	---------------	--------------------	---	-----------	---



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 12026	Mechanism Name: ASCP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Tajikistan	100,000

Total All Funding Sources: 100,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	100,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	12026		
Mechanism Name:	ASCP		
Prime Partner Name:	American Society of Clinical Pathology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12027	Mechanism Name: Strategic Information
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0
Kyrgyzstan	0
Tajikistan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12027		
Mechanism Name:	Strategic Information		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12746	Mechanism Name: Quality Health Care Project
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0
Kyrgyzstan	0
Tajikistan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0
Kazakhstan	GHP-USAID	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12746			
Mechanism Name: Quality Health Care Project			
Prime Partner Name: Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12772	Mechanism Name: UNODC
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Office on Drugs and Crime	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0
Kyrgyzstan	0
Tajikistan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12772			
Mechanism Name: UNODC			
Prime Partner Name: United Nations Office on Drugs and Crime			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12799	Mechanism Name: Support to Ministry of Health/Republican AIDS Center of the Republic of Tajikistan
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health/Republican AIDS Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Tajikistan	300,000

Total All Funding Sources: 300,000		
---	--	--



Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	300,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12799		
Mechanism Name:	Support to Ministry of Health/Republican AIDS Center of the Republic of Tajikistan		
Prime Partner Name:	Ministry of Health/Republican AIDS Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	35,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	70,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	145,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12812	Mechanism Name: Support to Ministry of Health/Republican Narcology Center of the Kyrgyz Republic
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health/Republican Narcology Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Kyrgyzstan	350,000

Total All Funding Sources: 350,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	350,000

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12812		
Mechanism Name:	Support to Ministry of Health/Republican Narcology Center of the		
Prime Partner Name:	Kyrgyz Republic		
	Ministry of Health/Republican Narcology Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12859	Mechanism Name: USAID Dialogue on HIV and TB Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0
Kyrgyzstan	0
Tajikistan	0
Uzbekistan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12859
Mechanism Name:	USAID Dialogue on HIV and TB Project
Prime Partner Name:	Population Services International



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2015	2016
Central Asia Region	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,771	
Central Asia Region	KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,068	
Central Asia Region	KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,233	
Central Asia Region	KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	470	



		minimum standards required)		
--	--	-----------------------------	--	--

Implementing Mechanism Details

Mechanism ID: 12872	Mechanism Name: Columbia University (Columbia Treatment and Care)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0
Kyrgyzstan	0
Tajikistan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



(No data provided.)

Budget Code Information

Mechanism ID:	12872		
Mechanism Name:	Columbia University (Columbia Treatment and Care)		
Prime Partner Name:	Columbia University Mailman School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12889	Mechanism Name: Support to Ministry of Health/Republican AIDS Center of the Republic of Kazakhstan
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health/Republican AIDS Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC



Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12889		
Mechanism Name:	Support to Ministry of Health/Republican AIDS Center of the Republic of Kazakhstan		
Prime Partner Name:	Ministry of Health/Republican AIDS Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13501	Mechanism Name: Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kyrgyzstan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kyrgyzstan	GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13501



Mechanism Name:	Peace Corps		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13970	Mechanism Name: CLSI (under the former Lab Coalition mechanism)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	100,000
Kyrgyzstan	200,000
Tajikistan	0

Total All Funding Sources:		
300,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	300,000

Sub Partner Name(s)

Custom



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13970			
Mechanism Name: CLSI (under the former Lab Coalition mechanism)			
Prime Partner Name: Clinical and Laboratory Standards Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	300,000	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2015	2016	Planning Budget Targets
Central Asia Region	LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	11		Redacted
Central Asia	LAB_ACC_DSD	By site support type: Technical	11		Redacted



Region		Assistance-only (TA)			
Central Asia Region	LAB_ACC_DSD	Sum of Support Type disaggregates	11		Redacted
Central Asia Region	LAB_ACC_TA	Sum of Support Type disaggregates	11		Redacted

Implementing Mechanism Details

Mechanism ID: 13971	Mechanism Name: Republican Blood Center - Kazakhstan
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Republican Blood Center of the Ministry of Health of the Republic of Kazakhstan	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13971		
Mechanism Name:	Republican Blood Center - Kazakhstan		
Prime Partner Name:	Republican Blood Center of the Ministry of Health of the Republic of Kazakhstan		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13972	Mechanism Name: Republican Blood Center - Kyrgyzstan
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Republican Blood Center of the Ministry of Health of the Kyrgyz Republic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
Kyrgyzstan	100,000

Total All Funding Sources:		
100,000		



Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	100,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13972		
Mechanism Name:	Republican Blood Center - Kyrgyzstan		
Prime Partner Name:	Republican Blood Center of the Ministry of Health of the Kyrgyz Republic		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13973	Mechanism Name: Health Policy Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0
Kyrgyzstan	0
Tajikistan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13973			
Mechanism Name: Health Policy Project			
Prime Partner Name: Futures Group			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	IDUP	0	0
------------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13974	Mechanism Name: Grant Management Solutions (GMS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	25,000
Kyrgyzstan	100,000
Tajikistan	75,000

Total All Funding Sources: 200,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	200,000

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13974		
Mechanism Name:	Grant Management Solutions (GMS)		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13978	Mechanism Name: Republican Blood Center - Tajikistan
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Republican Blood Center of the Ministry of Health of the Republic of Tajikistan	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Benefiting Country	Benefiting Country Planned Amount
--------------------	-----------------------------------



Tajikistan	100,000
------------	---------

Total All Funding Sources: 100,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	100,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13978		
Mechanism Name:	Republican Blood Center - Tajikistan		
Prime Partner Name:	Republican Blood Center of the Ministry of Health of the Republic of Tajikistan		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17050	Mechanism Name: UNAIDS
Funding Agency: USAID	Procurement Type: Umbrella Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	25,000
Kyrgyzstan	75,000
Tajikistan	75,000

Total All Funding Sources: 175,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-USAID	175,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	43,750
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	43,750
Focus Area:	Collection and use of strategic information on SWs



	and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17050			
Mechanism Name: UNAIDS			
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	175,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17051	Mechanism Name: HIV REACT
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: AIDS Foundation East, West	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0
Kyrgyzstan	0
Tajikistan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17051			
Mechanism Name: HIV REACT			
Prime Partner Name: AIDS Foundation East, West			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2015	2016
Central Asia Region	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,700	
Central Asia Region	KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,700	

Implementing Mechanism Details

Mechanism ID: 17067	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17447	Mechanism Name: Health Finance & Governance
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	0
Kyrgyzstan	0
Tajikistan	0

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17447			
Mechanism Name: Health Finance & Governance			
Prime Partner Name: Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17565	Mechanism Name: Technical Assistance Services to Countries Supported by PEPFAR and the Global Fund
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	874,999
Kyrgyzstan	1,240,000
Tajikistan	1,340,001

Total All Funding Sources: 3,455,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	3,455,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17565 Mechanism Name: Technical Assistance Services to Countries Supported by PEPFAR and the Global Fund Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	850,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	305,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	900,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	650,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17776	Mechanism Name: Tajikistan - Republican Narcology Center
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health/Republican Narcology Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Tajikistan	250,000

Total All Funding Sources: 250,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	250,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



(No data provided.)

Budget Code Information

Mechanism ID: 17776			
Mechanism Name: Tajikistan - Republican Narcology Center			
Prime Partner Name: Ministry of Health/Republican Narcology Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17777	Mechanism Name: Kazakhstan - Republican Narcology Center
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health/Republican Narcology Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	100,000

Total All Funding Sources: 100,000		
---	--	--



Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	100,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17777		
Mechanism Name:	Kazakhstan - Republican Narcology Center		
Prime Partner Name:	Ministry of Health/Republican Narcology Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17778	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17812	Mechanism Name: Good Governance Initiative Fund (GGIF)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	40,000
Tajikistan	60,000

Total All Funding Sources: 100,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-USAID	100,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	5,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	5,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: MSM and TG	25,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17812			
Mechanism Name: Good Governance Initiative Fund (GGIF)			
Prime Partner Name: New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	25,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17813	Mechanism Name: LINKAGES
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	50,000
Kyrgyzstan	100,000
Tajikistan	150,000

Total All Funding Sources: 300,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-USAID	300,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	45,000
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	45,000
Focus Area:	Collection and use of strategic information on SWs



	and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17813 Mechanism Name: LINKAGES Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	225,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18124	Mechanism Name: UNODC
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Office on Drug and Crime (UNODC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

Benefiting Country	Benefiting Country Planned Amount
Kazakhstan	25,000
Kyrgyzstan	50,000
Tajikistan	75,000

Total All Funding Sources: 150,000		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-USAID	150,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	18124		
Mechanism Name:	UNODC		
Prime Partner Name:	United Nations Office on Drug and Crime (UNODC)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	150,000	0



Systems			
---------	--	--	--

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18155	Mechanism Name: LEADER for PLHIV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Managing Country	Funding Source	Funding Amount
Kazakhstan	GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID: 18155 Mechanism Name: LEADER for PLHIV Prime Partner Name: Futures Group			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		3,000		3,000	0
ICASS		601,000		601,000	0
Indirect Costs		200,000		200,000	0
Management Meetings/Professional Development		65,000		65,000	0
Non-ICASS Administrative Costs		28,738		28,738	0
Staff Program Travel		86,550		86,550	0
USG Staff Salaries and Benefits		972,067		972,067	0
Total	0	1,956,355	0	1,956,355	0

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
USG Staff Salaries and Benefits	505,625	2,139,375		2,645,000	0
Total	505,625	2,139,375	0	2,645,000	0



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		20,000		20,000	0
Computers/IT Services		8,000		8,000	0
ICASS		12,000		12,000	0
Management Meetings/Professional Development		9,000		9,000	0
Non-ICASS Administrative Costs		96,000		96,000	0
Staff Program Travel		36,000		36,000	0
USG Staff Salaries and Benefits		99,000		99,000	0
Total	0	280,000	0	280,000	0

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Management Meetings/Professional Development		3,500		3,500	0
Peace Corps Volunteer Costs		87,500		87,500	0



Staff Program Travel		4,000		4,000	0
USG Staff Salaries and Benefits		25,000		25,000	0
Total	0	120,000	0	120,000	0